Broncus Holding Corp

Capital Structure and Liquidity Broncus Holding Corp maintains a strong liquidity position, with a current ratio of 22.7, indicating a significant buffer of current assets over current liabilities. The company holds $31.7 million in cash and equivalents, while long-term debt is minimal at $16,000. This liquidity profile supports operational flexibility and reduces immediate refinancing risk. ### Profitability and Returns The company is currently unprofitable, with a net loss of $17.9 million and a return on equity (ROE) of -11.92%. These figures are below the typical performance of the Advanced Medical Equipment & Technology industry, which generally expects positive ROE and gross margins above 40%. The negative operating income of $17.87 million and a return on assets (ROA) of -11.45% further highlight the company's underperformance relative to industry norms. ### Segments and Geographic Exposure Broncus operates in the domestic and overseas markets, with a focus on lung cancer, COPD, and other lung disease treatment products. The company's revenue is not disclosed by segment, but its product pipeline suggests a concentration in interventional pulmonary therapies. The geographic exposure is not quantified in the input data, but the company's operations span both local and international markets. ### Growth Trajectory The company's growth trajectory is constrained by its current financial performance, with a negative operating cash flow of $9.98 million and a free cash flow of -$15.92 million. While the company is investing in R&D and capital expenditures, the lack of positive revenue growth and profitability signals a challenging path to expansion. Analysts have issued one "Buy" recommendation, with no "Strong Buy" or "Sell" ratings, indicating a cautious outlook. ### Risk Factors The company faces moderate operational risk due to its unprofitable status and negative cash flows. However, the risk of dilution is low, with no immediate filing-based flags detected. The company's capital structure is stable, with no significant debt obligations, and the absence of dilutive securities in the near term reduces shareholder dilution risk. ### Recent Events Recent filings and transcripts do not indicate any material events that would significantly alter the company's financial or operational outlook. The company continues to focus on its pipeline of medical devices, with no major regulatory or legal challenges reported in the latest disclosures.